Yüklüyor......
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers that might predict the response to cetuximab treatment. Fifty-three wild-type KRAS exon 2 mCRC patients were treated wi...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5008360/ https://ncbi.nlm.nih.gov/pubmed/26989027 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8076 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|